Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00193479 · ClinicalTrials.gov registry record · Phase 2
Combination Chemotherapy and Rituximab With Pegfilgrastim Followed by Rituximab, in Large B-Cell Non-Hodgkin's Lymphoma
A Phase 2 study, sponsored by SCRI Development Innovations.
- Completed
- Registry status
- Phase 2
- Development phase
- 51
- Enrollment target
NCT00193479 is a Phase 2 study that has completed, run by SCRI Development Innovations. The registered enrollment target is 51 participants.
The verdict
NCT00193479, a Phase 2 study, has completed, sponsored by SCRI Development Innovations.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 51 participants
- Enrollment target
Study Summary
The purposes of this trial are to decrease toxicity and improve treatment effectiveness elderly patients. With a short course of chemotherapy with cyclophosphamide, mitoxantrone, vincristine, and prednisone with concurrent administration of rituximab it is likely to be as effective as longer programs, and will certainly be better tolerated by this patient group. The addition of maintenance therapy may result in substantial prolongation of remission duration.
Interventions
- DRUG Cyclophosphamide
- DRUG Rituximab
- DRUG Vincristine
- DRUG Prednisone
- DRUG Mitoxantrone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2003-04 |
| Est. Completion | 2010-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00193479
The ClinicalTrials.gov registry entry for NCT00193479 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SCRI Development Innovations, which has 146 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT00193479 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00193479 about?
NCT00193479 is a clinical study titled "Combination Chemotherapy and Rituximab With Pegfilgrastim Followed by Rituximab, in Large B-Cell Non-Hodgkin's Lymphoma". The purposes of this trial are to decrease toxicity and improve treatment effectiveness elderly patients. With a short course of chemotherapy with cyclophosphamide, mitoxantrone, vincristine, and prednisone with concurrent administration of rituximab it is likely to be as effective as longer program...
What is the current status of trial NCT00193479?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 51 participants. The study started on 2003-04. Estimated completion is 2010-02.
What interventions are being tested in trial NCT00193479?
The interventions under investigation include: Cyclophosphamide (DRUG), Rituximab (DRUG), Vincristine (DRUG), Prednisone (DRUG), Mitoxantrone (DRUG).
Who is sponsoring clinical trial NCT00193479?
This trial is sponsored by SCRI Development Innovations, which has 146 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.